Legend Biotech (LEGN) Projected to Post Earnings on Wednesday

Legend Biotech (NASDAQ:LEGN) is expected to post its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Legend Biotech to post earnings of ($0.08) per share and revenue of $277.9080 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:00 AM ET.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.12). Legend Biotech had a negative net margin of 40.83% and a negative return on equity of 32.00%. The business had revenue of $255.06 million for the quarter, compared to the consensus estimate of $237.49 million. During the same quarter in the previous year, the business earned ($0.05) earnings per share. The firm’s revenue was up 36.8% on a year-over-year basis. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Legend Biotech Stock Down 0.2%

Shares of NASDAQ LEGN opened at $32.05 on Wednesday. Legend Biotech has a one year low of $27.34 and a one year high of $47.79. The company has a debt-to-equity ratio of 0.30, a current ratio of 4.71 and a quick ratio of 4.57. The firm’s 50 day simple moving average is $33.19 and its two-hundred day simple moving average is $34.47. The stock has a market capitalization of $5.92 billion, a P/E ratio of -36.42 and a beta of 0.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LEGN. Canada Pension Plan Investment Board bought a new position in Legend Biotech during the 2nd quarter valued at approximately $15,790,000. Bank of America Corp DE lifted its stake in Legend Biotech by 52.1% in the second quarter. Bank of America Corp DE now owns 255,986 shares of the company’s stock worth $9,085,000 after acquiring an additional 87,707 shares during the period. Squarepoint Ops LLC lifted its stake in Legend Biotech by 77.6% in the second quarter. Squarepoint Ops LLC now owns 148,681 shares of the company’s stock worth $5,277,000 after acquiring an additional 64,956 shares during the period. LMR Partners LLP purchased a new stake in Legend Biotech in the second quarter worth $2,129,000. Finally, Alliancebernstein L.P. lifted its stake in Legend Biotech by 3.5% in the second quarter. Alliancebernstein L.P. now owns 1,560,596 shares of the company’s stock worth $55,386,000 after acquiring an additional 52,344 shares during the period. Institutional investors own 70.89% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on LEGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Legend Biotech in a research report on Wednesday, October 8th. Cantor Fitzgerald began coverage on Legend Biotech in a report on Tuesday, October 7th. They set an “overweight” rating and a $40.00 target price for the company. Royal Bank Of Canada restated an “outperform” rating and set a $77.00 target price (up from $75.00) on shares of Legend Biotech in a report on Tuesday, August 12th. HC Wainwright dropped their target price on Legend Biotech from $75.00 to $60.00 and set a “buy” rating for the company in a report on Friday, October 17th. Finally, Morgan Stanley increased their target price on Legend Biotech from $81.00 to $83.00 and gave the company an “overweight” rating in a report on Tuesday, August 12th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $66.56.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).